中国体内放射性药物的现状与展望  

PRESENT STATUS AND PROSPECT IN VIVO RADIOPHARMACEUTICALS IN CHINA

作　　者：刘伯里[1] 金昱泰[1] 

机构地区：[1]北京师范大学化学系

出　　处：《核化学与放射化学》1989年第4期229-235,共7页Journal of Nuclear and Radiochemistry

摘　　要：本文扼要介绍我国十年来体内放射性药物的进展。诊断和治疗用体内放射性药物的发展很迅速,已有反应堆生产与加速器生产的系列医用放射性核素及放射性药物,尤其是^(99m)Tc标记的脑、心灌注显像剂、放射免疫显像剂等。本文还对今后的发展提出一些建议与展望。The radiopharmaceutical chemistry is an important part in applied radio-chemistry. In this paper is given a review of in vivo radiopharmaceuticals in our country in recent years. It should be pointed out that in vivo radiopharmaceuticals including diagnostic and therapeutic have enjoyed rapid development. Recently, a series of reactor and cyclotron produced medical radionuclides and their radiopharmaceuticals, especially new 99mTc labelled brain perfusion imaging agents 99mTc-dl-HMPAO, 99mTc-ECD, myocardial perfusion imaging agents 99mTc-CPI and MIBI, radioimmunoimaging agents etc. have heen reported. Furthermore, R and D suggestions and future trends are discussed.

关 键 词：体内 放射性药物 现状 展望 

分 类 号：R81[医药卫生—放射医学]